Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc (NY: ZYME )

6.120 -0.180 (-2.86%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 467,414
Open 6.300
Bid (Size) 6.030 (1)
Ask (Size) 7.100 (1)
Prev. Close 6.300
Today's Range 6.060 - 6.320
52wk Range 4.560 - 39.41
Shares Outstanding 57,771,204
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
From Zymeworks Inc.
Via Business Wire

Performance

YTD
-63.96%
-63.96%
1 Month
-10.92%
-10.92%
3 Month
-11.82%
-11.82%
6 Month
-61.31%
-61.31%
1 Year
-83.17%
-83.17%

More News

Read More
Analyst Ratings for Zymeworks
Via Benzinga
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
Zymeworks Turns Down All Blue's Hostile Bid
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
From Zymeworks Inc.
Via Business Wire
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
From Zymeworks Inc.
Via Business Wire
Market Selloff
Via Talk Markets
Where Zymeworks Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Via Benzinga
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Earnings Scheduled For May 4, 2022
Via Benzinga
Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop
Via InvestorPlace
5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins
Via Benzinga
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
70 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Is Zymeworks (ZYME) Stock Surging 30% Today?
Via InvestorPlace
Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points
Via Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.